Deals

Sanofi and Regeneron Expand Alliance with $8B Next‑Generation Antibody Collaboration – Four Long‑Acting Type 2 Inflammation Programs Added Alongside Dupixent
Multi-specific antibodiesNASDAQ: REGN

Sanofi and Regeneron Expand Alliance with $8B Next‑Generation Antibody Collaboration – Four Long‑Acting Type 2 Inflammation Programs Added Alongside Dupixent

Sanofi (NASDAQ: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a major expansion of their more than 20‑year antibody collaboration, adding four next‑generation, long‑acting antibodies targeting the type 2 inflammation…

Shionogi to Acquire IntraBio for $2.0B – Rare Neurodegenerative Disease Platform Anchored by FDA‑Approved AQNEURSA Expands Global Portfolio

Shionogi to Acquire IntraBio for $2.0B – Rare Neurodegenerative Disease Platform Anchored by FDA‑Approved AQNEURSA Expands Global Portfolio

Foghorn Therapeutics and Lilly Discontinue FHD‑909 and SMARCA2 Programs – Gene Traffic Control Collaboration Ends After Phase 1 Review

Foghorn Therapeutics and Lilly Discontinue FHD‑909 and SMARCA2 Programs – Gene Traffic Control Collaboration Ends After Phase 1 Review

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
AIE-Health Now

E-Health Now Secures USD 13.8 Million in Series C Financing to Expand AI Medical Services

AusperBioFinance

AusperBio Secures $37 Million in Series A Funding to Advance Hepatitis B Therapy AHB-137

Duoning Biotechnology

Shanghai Duoning Biotechnology Partners with BASF SE to Commercialize Medical Materials in China

Baheal Pharmaceutical

Baheal Pharmaceutical Group to Launch Industry Fund Focused on Life Sciences

Show More